<scp>AL</scp>3810, a multi‐tyrosine kinase inhibitor, exhibits potent anti‐angiogenic and anti‐tumour activity <i>via</i> targeting <scp>VEGFR</scp>,<scp> FGFR</scp> and <scp>PDGFR</scp>
Journal of Cellular and Molecular Medicine